Sign in

You're signed outSign in or to get full access.

JH

Jaguar Health, Inc. (JAGX)·Q3 2024 Earnings Summary

Executive Summary

  • Q3 2024 net revenue was approximately $3.1M, up 14% quarter-over-quarter and 11% year-over-year, driven primarily by Mytesi; Mytesi prescriptions rose 10.9% QoQ and 2.7% YoY .
  • Operating loss improved YoY to $7.3M (vs $8.8M), but net loss widened to $9.9M due to higher fair value losses despite lower interest expense (FVO accounting) .
  • Management highlighted near-term catalysts: SABCS poster on Phase 3 OnTarget breast cancer subgroup results (Dec 11, 2024), initiation of two Phase 2 trials (MVID and SBS-IF), and the U.S. commercial launch of Gelclair in October 2024; the Board stated it has “no intention” to pursue a reverse split .
  • No formal quantitative guidance provided; Wall Street consensus estimates via S&P Global were unavailable for Q3 2024, so we cannot assess beats/misses versus estimates.

What Went Well and What Went Wrong

What Went Well

  • Revenue acceleration and prescription momentum: “net third quarter 2024 revenue of approximately $3.1 million increased approximately 14% versus the net in the second quarter of 2024… and approximately 11% versus net Q3 2023,” with Mytesi prescription volume +10.9% QoQ .
  • Clinical/regulatory progress: OnTarget Phase 3 subgroup results in breast cancer accepted for SABCS poster; plan to brief FDA and request a meeting in H1 2025 to discuss regulatory pathways for subgroup approval .
  • Commercial expansion: Initiated U.S. launch of Gelclair (oral mucositis); early prescriber engagement (nurse practitioners) and oncology conference presence support adoption .

What Went Wrong

  • Profitability deterioration on a net basis: Net loss increased to ~$9.9M vs ~$7.8M YoY; non-GAAP recurring EBITDA loss widened (press release: $8.2M loss vs $6.2M prior year; CFO on call referenced $9.2M loss), highlighting a discrepancy to monitor .
  • Higher non-operating volatility: Loss from change in fair value of financial/hybrid instruments increased to ~$3.1M from ~$2.2M, offsetting benefit from lower interest expense due to FVO accounting .
  • OnTarget did not meet the primary endpoint across all solid tumors, constraining the breadth of initial label expansion; strategy pivots to defined subgroups (breast, lung) .

Financial Results

Quarterly Performance (oldest → newest)

MetricQ1 2024Q2 2024Q3 2024
Total Net Revenue ($USD Millions)~$2.4 ~$2.72 ~$3.1
Loss from Operations ($USD Millions)$8.2 $7.2 $7.3
Net Loss ($USD Millions)$9.2 $9.5 $9.9

YoY Operating Metrics (Q3 2023 vs Q3 2024)

MetricQ3 2023Q3 2024
Cost of Product Revenue ($USD Millions)~$0.51 ~$0.54
R&D Expense ($USD Millions)~$6.1 ~$4.0
Sales & Marketing Expense ($USD Millions)~$1.5 ~$2.0
G&A Expense ($USD Millions)~$3.5 ~$3.8
Loss from Operations ($USD Millions)~$8.8 ~$7.3
Net Loss ($USD Millions)~$7.8 ~$9.9
Change in Fair Value Loss ($USD Millions)~$2.2 ~$3.1
Interest Expense/Income ($USD Millions)~$0.5 expense ~$0.2 net interest income
Non-GAAP Recurring EBITDA (Loss) ($USD Millions)~$6.2 ~$8.2 (press release)

Revenue Components (oldest → newest)

ComponentQ3 2023Q2 2024Q3 2024
Mytesi Net Revenue ($USD Millions)~$2.8 ~$2.6 ~$3.0
License Revenue ($USD)$42,000 $42,000 $42,000
Deferred Revenue (balance at 9/30/2024)——$765,000

KPIs

KPIQ3 2024Reference
Mytesi Prescription Volume QoQ+10.9%
Mytesi Prescription Volume YoY+2.7%
Neonorm (non-prescription) RevenuesMinimal (Q3 2024, Q3 2023)

Notes:

  • CFO on the call cited non-GAAP recurring EBITDA loss of $9.2M for Q3 2024, differing from the press release’s $8.2M; company should reconcile this discrepancy .

EPS and Margins vs Estimates

  • EPS/margin data not disclosed in the press release or transcript; Wall Street consensus via S&P Global was unavailable, so we cannot provide comparisons or determine beats/misses.

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
RevenueQ4 2024 / FY 2024Not providedNot providedMaintained (no formal guidance)
Operating ExpensesQ4 2024 / FY 2024Not providedNot providedMaintained (no formal guidance)
Gelclair LaunchQ4 2024Planned October launchLaunched October; revenue contribution to be reported in 2025Implemented
Corporate Action: Reverse SplitNear-termN/A“No intention of implementing a reverse split”Clarified stance
Regulatory: FDA Meeting (CTD subgroup)H1 2025 (planned)N/APlan to request meeting with FDA GI division H1 2025New timeline

Earnings Call Themes & Trends

TopicPrevious Mentions (Q1, Q2)Current Period (Q3)Trend
OnTarget Phase 3 outcomes and strategyQ1: top line “imminent”; broad basket design; supportive care paradigm . Q2: clinically meaningful signals in breast/lung subgroups; responder analysis details .Breast cancer subgroup results accepted for SABCS; plan FDA briefing and meeting H1 2025; acknowledgment overall primary endpoint not met .Focus narrowing to defined subgroups; regulatory engagement escalates.
Cancer supportive care expansion (Gelclair)Q1: in-licensed; strong HCP interest; exhibit plans (ONS, ASCO) . Q2: October launch plan; head & neck focus .U.S. launch initiated in October; early prescriber engagement (nurse practitioners, radiation oncology) .Commercial execution underway; adoption building.
Rare/Orphan programs (MVID, SBS-IF)Q1: multi-continental clinical strategy; early access in EU contemplated . Q2: EU EMA clearance for SBS-IF; IITs US/MENA; novel formulation .Two Phase 2 trials initiating Q4; multiple IITs with results expected late 2024/early 2025 .Program momentum increasing; potential near-term PoC readouts.
Capital markets/Reverse split stance——Board has “no intention” to implement reverse split given catalysts .
Partnerships/Institutional investor outreach—Q2: growth strategy led hire .Active BD discussions and institutional outreach; global rights retained .

Management Commentary

  • “Net third quarter 2024 revenue of approximately $3.1 million increased approximately 14% versus the… second quarter… and approximately 11% versus net Q3 2023.”
  • “We achieved significant results… in the prespecified subgroup of breast cancer patients… accepted for a poster… at the San Antonio Breast Cancer Symposium.”
  • “Jaguar’s board of directors has no intention of implementing a reverse split of the Company’s common stock.”
  • “We plan to request a meeting with the GI division of the FDA in the first half of 2025 to discuss potential regulatory pathways for crofelemer approval for the subgroup of breast cancer patients.”
  • “Jaguar launched the FDA-approved oral mucositis prescription product, Gelclair, our third commercialized prescription product.”

Q&A Highlights

  • Partnerships and institutional investors: Management is actively reintroducing the story to institutions globally; retains global, unencumbered rights to crofelemer and is balancing potential non-dilutive BD against long-term value of retaining commercialization .
  • OnTarget Stage 2 extension data: Focus remains on Stage 1 responder analysis; subset Stage 2 analysis expected in 3–6 months to inform FDA discussion, with full study analyses into mid/late next year .
  • FDA process/timing: Meetings cannot be “fast-tracked”; potential for fast-track/breakthrough designation pertains to development pathway, not scheduling .
  • Profitability path: Mytesi contributes positively; Gelclair targeted to contribute; blockbuster opportunities focus on supportive care unmet needs; risk mitigation via late-stage development around an already-approved Active Ingredient and known safety .
  • Reverse split stance reiterated: Board has no intention to implement a reverse split given near-term catalysts .

Estimates Context

  • Wall Street consensus via S&P Global for Q3 2024 EPS and revenue was unavailable, so we cannot assess beats/misses or provide estimate comparisons. Management did not provide formal financial guidance in the press release or call .

Key Takeaways for Investors

  • Revenue inflected positively with sequential and YoY gains; watch for Gelclair revenue contribution beginning Q4/Q1 reporting cycles .
  • Regulatory narrative evolves toward subgroup approvals: SABCS breast cancer data and H1 2025 FDA meeting plan are near-term catalysts; monitor subsequent publications and briefing progress .
  • Rare disease programs (MVID, SBS-IF) could deliver PoC signals in late 2024/early 2025 and may enable EU early access; commercial model differs (higher pricing, orphan dynamics) .
  • Profitability remains challenged: Net loss widened; non-GAAP recurring EBITDA loss increased; track OpEx trends (S&M and G&A up) and fair value/derivatives impacts .
  • Mytesi prescription growth is a positive operational KPI; continued Rx momentum and closed network inventory dynamics should be monitored for revenue translation .
  • Capital markets messaging: “No reverse split” stance reduces mechanical overhang; management is pursuing institutional engagement and evaluating partnering for non-dilutive capital .
  • Without consensus estimates, trading setups hinge on discrete catalysts (SABCS, FDA interactions, Phase 2/IIT readouts) and Gelclair traction; risk management should account for volatility tied to fair value accounting and clinical outcomes .